ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO309

Patient Reported Outcomes (PRO) Among Patients Receiving Home Hemodialysis (HHD) with the Tablo® Hemodialysis System

Session Information

  • Home Dialysis - I
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 802 Dialysis: Home Dialysis and Peritoneal Dialysis


  • Wazny, Jarnet Han, Outset Medical, San Jose, California, United States
  • Holmes, Christie D., Outset Medical, San Jose, California, United States
  • D'Alessandri-Silva, Cynthia J., Outset Medical, San Jose, California, United States
  • Chertow, Glenn, Stanford University School of Medicine, Stanford, California, United States

The HOME Registry is an ongoing observational (“real world”) study of patients with kidney failure utilizing the Tablo® Hemodialysis System (Tablo) for home hemodialysis (HHD). To date, relatively few studies have evaluated patient-reported outcomes among patients receiving HHD.


We evaluated the first 55 patients on Tablo HHD using an ePRO software at 1-, 3-, 6- and 12-month visits using: 1) Physical Health Composite (PHC) and 2) Mental Health Composite (MHC) scores from the Medical Outcomes Study Short Form 12 (SF-12) along with the 3) insomnia total score from the Insomnia Severity Index (ISI). We employed mixed effects regression for repeated measurements, using specific covariance matrix structures to allow for model convergence and to optimize model fit. We analyzed time (visit) as a fixed effect and age, designated race, education, employment, and care partner type as random effects.


The mean patient age was 57.4 years old. The demographic composition was 76% men, 5.5% Black, 9% Hispanic/Latino, 39% with less than college degree attainment, 69% AV fistula, and 45% having transitioned from in-center HD. The SF-12 PHC and ISI had positive correlations with time, at p=0.046 and p=0.0035, respectively. Every 1 month increase in time was associated with a 0.417 increase in the SF-12 PHC and a 0.272 decrease in ISI score. There was no significant relation between time and the SF-12 MHC (p=0.19). Figure 1 shows modeled results for ISI and SF-12 PHC and MHC.


Preliminary results show favorable effects of Tablo-enabled HHD on self-reported physical health and symptoms of insomnia. Longer term follow-up in a larger patient sample will further elucidate the benefits of Tablo-enabled HHD on functional capacity, symptoms, and well-being.